Short answer
Foghorn Therapeutics Inc. (FHTX) filed its Q3 2025 10-Q quarterly report on Nov 5, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $8M (up 4.4% year over year) with net income of −$16M.
Q3 2025 key financials · XBRL
- Revenue
- $8M
- +4.4% YoY · +7.9% QoQ
- Net income
- −$16M
- +17.1% YoY · +11.6% QoQ
- Operating margin
- -226.9%
- EPS (diluted)
- −$0.26
- +0.0% YoY · +7.1% QoQ
Source: XBRL data from the Foghorn Therapeutics Inc. (FHTX) Q3 2025 10-Q on SEC EDGAR. USD.
Foghorn Therapeutics Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Collaboration revenue $8.2M, up $0.4M from $7.8M YoY
- Net loss $15.8M vs $19.1M YoY; operating loss $18.5M vs $23.9M
- Lilly partnered programs highest R&D spend at $6.7M, up $0.4M YoY
- FHD-286 lowest R&D spend at $(1.0)M, down $3.4M YoY after discontinuation
- R&D expenses $20.0M vs $24.7M; FHD-909 enrollment expected to increase costs
Risk Factors
- No material changes to 2024 Form 10-K risk factors
- Carried-forward risks remain the principal regulatory, legal, operational, competitive, and financial exposures
- No new or modified director or officer Rule 10b5-1 trading arrangements during three months ended September 30, 2025
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Foghorn Therapeutics Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.